Leveraging the FAERS Dashboard for Proactive Cosmetic Safety Risk Mitigation

The New Transparency Paradigm Under MoCRA

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) fundamentally altered the regulatory landscape for cosmetic manufacturers, distributors, and private-label brands. Among its most consequential—and underappreciated—provisions is the mandatory reporting of serious adverse events to the FDA within fifteen business days of receipt. These reports, once filed, do not disappear into a regulatory vacuum. They become part of a searchable, publicly accessible adverse event database that the agency maintains and updates.

For years, sophisticated pharmaceutical and medical device companies have monitored FDA adverse event data as a matter of routine pharmacovigilance practice. Cosmetic companies, by contrast, operated for decades without any comparable statutory reporting obligation or public data repository. MoCRA closes that gap. Companies that fail to recognize this shift—and continue treating adverse event compliance as a narrow, reactive filing exercise—are missing a significant opportunity, and exposing themselves to avoidable risk.

Understanding the Public Adverse Event Dashboard

The FDA's adverse event dashboard—often referred to colloquially as FAERS, though the cosmetics-specific data resides within the CFSAN Adverse Event Reporting System (CAERS)—aggregates reports submitted by consumers, healthcare providers, and now, mandatorily, by responsible persons under MoCRA. The dashboard allows searches by product category, reported symptom, and time period, and is refreshed on a regular cadence.

This is not a static repository. It is a living dataset that regulators, plaintiffs' counsel, consumer advocacy organizations, and competitors can and do mine for patterns. A cluster of reports involving a particular ingredient, product line, or symptom profile is visible to anyone with an internet connection—not merely to the company that filed the report.

From Compliance Tool to Business Intelligence Asset

The strategic implication is straightforward: the dashboard should be monitored not only for a company's own products, but across the category in which it competes. Emerging adverse event signals involving comparable formulations, shared ingredients, or similar product claims often precede broader regulatory attention or plaintiff-side investigation.

A disciplined monitoring program should include:

• Periodic structured searches of the dashboard by ingredient, product category, and relevant Code of Federal Regulations classification
• Tracking of symptom clusters that may indicate formulation, packaging, or labeling issues rather than isolated idiosyncratic reactions
• Comparison of internally logged adverse events against what ultimately appears in the public dataset, to confirm reporting accuracy and completeness
• Competitive intelligence gathering on ingredient classes used across a company's portfolio, even where the specific product has not generated a report

Treating this as a quarterly business review item—alongside quality, regulatory, and legal functions—elevates adverse event monitoring from a compliance afterthought to a genuine risk management discipline.

Building a Proactive Safety Substantiation Strategy

MoCRA codifies a requirement that responsible persons maintain adequate substantiation supporting a reasonable certainty that a cosmetic product is safe under its labeled conditions of use. This substantiation obligation does not exist in isolation from adverse event data; the two are deeply intertwined.

When the public dashboard reveals an emerging signal—even one involving a competitor's product with a comparable ingredient profile—that is the moment to revisit and, where necessary, supplement existing safety substantiation files. Waiting until a company's own product generates multiple reports, or until FDA correspondence arrives, cedes control of the narrative and the timeline.

A proactive substantiation posture includes:

• Periodic refresh of toxicological and clinical data supporting key ingredients, particularly those subject to evolving scientific literature
• Documentation of the rationale for concluding that existing substantiation remains adequate in light of new adverse event signals
• Clear internal records showing that adverse event review and substantiation review are linked processes, not siloed functions
• Engagement of qualified toxicologists or safety consultants to formally assess whether dashboard trends warrant additional testing or labeling adjustments

This documentation does double duty: it satisfies the statutory substantiation requirement and creates a contemporaneous record demonstrating diligence, which is invaluable if regulatory inquiry or litigation later arises.

Litigation and Regulatory Exposure Risks

Plaintiffs' firms have already demonstrated sophistication in mining public FDA databases to build mass tort theories in the pharmaceutical and device spaces. There is every reason to expect the same approach applied to cosmetics now that comparable public data exists. A pattern of adverse event reports, absent a demonstrable and well-documented response, can become powerful evidence of notice in a failure-to-warn or negligence claim.

Similarly, FDA's own risk-based inspection and enforcement priorities are increasingly informed by publicly available signals. A company that can show it identified a trend, evaluated it against current substantiation, and took appropriate action—whether that means enhanced labeling, formulation review, or additional consumer communication—occupies a dramatically stronger position than one that appears to have been caught unaware by its own public filings.

Practical Steps for Corporate Risk Management

Counsel advising cosmetic companies should consider recommending the following operational framework:

• Assign clear ownership of dashboard monitoring to a cross-functional team including regulatory affairs, quality assurance, and legal
• Establish a documented cadence for review, escalation criteria, and substantiation reassessment triggers
• Integrate dashboard findings into existing MoCRA recordkeeping systems so that the connection between monitoring and substantiation is auditable
• Conduct periodic mock audits simulating how the company's adverse event history and substantiation files would appear to an FDA investigator or opposing litigation counsel

Looking Ahead

MoCRA has effectively converted a once-private compliance obligation into a public data stream with strategic implications far beyond regulatory filing deadlines. Companies that treat the adverse event dashboard as a passive reporting mechanism will find themselves perpetually reactive. Those that treat it as a business intelligence asset—feeding continuous improvement in safety substantiation and informing risk-based decision-making—will be better positioned to withstand both regulatory scrutiny and the litigation environment that MoCRA's transparency requirements are likely to accelerate.